| Dr Robert Michael Eager, MD | |
|
34503 9th Ave S Ste 100, Federal Way, WA 98003-8726 | |
| (253) 835-8700 | |
| (253) 835-8000 |
| Full Name | Dr Robert Michael Eager |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 34503 9th Ave S Ste 100, Federal Way, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164628756 | NPI | - | NPPES |
| 0281327 | Other | WA | DEPT OF LABOR AND INDUSTRIES |
| P00958040 | Other | WA | RAILROAD MEDICARE |
| 2012921 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MDR-5279 (Hawaii) | Secondary |
| 207R00000X | Internal Medicine | MD60205862 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Assured Home Health | Seattle, WA | Home health agency |
| Emerald Healthcare Inc | Tacoma, WA | Home health agency |
| St Francis Community Hospital | Federal way, WA | Hospital |
| St Joseph Medical Center | Tacoma, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.
A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.
The survey, conducted by the Mercer consulting firm, found that retail and hospitality companies are bracing for the biggest cost increases.
Researchers at Duke University and the National Institutes of Health have found a way to calm the fears of anxious mice with a drug that alters their brain chemistry. They've also found that human genetic differences related to the same brain chemistry influence how well people cope with fear and stress.
Understanding the motivations that drive humans to eat is an important consideration in the development of weight loss therapies. Now a study led by researchers at Beth Israel Deaconess Medical Center helps explain how the diabetes and weight loss drug liraglutide acts on brain receptors to make enticing foods seems less desirable.
› Verified 7 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.
A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.
The survey, conducted by the Mercer consulting firm, found that retail and hospitality companies are bracing for the biggest cost increases.
Researchers at Duke University and the National Institutes of Health have found a way to calm the fears of anxious mice with a drug that alters their brain chemistry. They've also found that human genetic differences related to the same brain chemistry influence how well people cope with fear and stress.
Understanding the motivations that drive humans to eat is an important consideration in the development of weight loss therapies. Now a study led by researchers at Beth Israel Deaconess Medical Center helps explain how the diabetes and weight loss drug liraglutide acts on brain receptors to make enticing foods seems less desirable.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Michael Eager, MD 34503 9th Ave S Ste 100, Federal Way, WA 98003-8726 Ph: (253) 835-8700 | Dr Robert Michael Eager, MD 34503 9th Ave S Ste 100, Federal Way, WA 98003-8726 Ph: (253) 835-8700 |
News Archive
"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.
A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.
The survey, conducted by the Mercer consulting firm, found that retail and hospitality companies are bracing for the biggest cost increases.
Researchers at Duke University and the National Institutes of Health have found a way to calm the fears of anxious mice with a drug that alters their brain chemistry. They've also found that human genetic differences related to the same brain chemistry influence how well people cope with fear and stress.
Understanding the motivations that drive humans to eat is an important consideration in the development of weight loss therapies. Now a study led by researchers at Beth Israel Deaconess Medical Center helps explain how the diabetes and weight loss drug liraglutide acts on brain receptors to make enticing foods seems less desirable.
› Verified 7 days ago
Alain L Lambert, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 34503 9th Ave S Ste 100, Federal Way, WA 98003 Phone: 253-835-8700 Fax: 360-830-1385 | |
Peter Campbell Gregory, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 32014 32nd Ave S, Federal Way, WA 98001 Phone: 253-874-7107 Fax: 253-874-1923 | |
Delia Viisoreanu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 33501 1st Way S, Federal Way, WA 98003 Phone: 253-838-2400 Fax: 253-874-1634 | |
Dr. Shaista Quddusi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 S 320th St, Suite D, Federal Way, WA 98003 Phone: 253-880-1029 | |
Romana Shehzadi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 34503 9th Ave S Ste 130, Federal Way, WA 98003 Phone: 253-835-5340 Fax: 253-835-5350 | |
Dr. Sasha Oommen Joseph, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 34509 9th Ave S, Suite 107, Federal Way, WA 98003 Phone: 253-952-8349 Fax: 253-927-3049 | |
Dr. Rohan Sharma, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 34509 9th Ave S Ste 107, Federal Way, WA 98003 Phone: 253-952-8349 |